1. Mathematical models of targeted cancer therapy,;L. H. Abbott;British Journal of Cancer,2006
2. The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy,;S. Brandford;BLOOD,2003
3. Chronic myeloid leukemia,;M. D. Charles;The New England Journal of Medicine,1999
4. Eradication of chronic myeloid leukemia stem cells: A novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib,;J. Foo;PLoS Computational Biology,2009
5. Chronic myeloid leukemia: Standard treatment options,;D. Frame;American Journal of Health-System Pharmacy,2006